Long noncoding RNA semaphorin 6A-antisense RNA 1 reduces hepatocellular carcinoma by promoting semaphorin 6A mRNA degradation

Figure 1 Semaphorin 6A is upregulated in hepatocellular carcinoma and negatively correlated with semaphorin 6A-antisense RNA 1. A: Immunohistochemistry images of semaphorin 6A (SEMA6A) in tumor and adjacent non-tumor tissues from hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients (n = 47, 3 samples, scale bars indicate 20 μm); B: Quantitative analysis of immunohistochemical results; C: Relative expression of SEMA6A mRNA (tumor/non-tumor) in 47 pairs of clinical samples were measured by quantitative polymerase chain reaction; D: The correlation analysis of SEMA6A-AS1 and SEMA6A in HBV-related HCC (n = 47); E: Kaplan-Meier analysis of overall survival based on SEMA6A expression levels in HBV-related HCC patients. The median was used as the cutoff. ^cP < 0.001. SEMA6A: Semaphorin 6A; AS1: Antisense RNA 1.